Fresenius Lost Chance To Appeal Antitrust Suit, 3rd Circ. Told
By Hannah Albarazi ( February 5, 2021, 6:09 PM EST) -- Drugmaker Par Pharmaceutical urged the Third Circuit to deny health care company Fresenius Kabi USA's petition for a panel to rehear its antitrust case alleging Par delayed Fresenius from marketing a generic blood pressure medication, saying Thursday that Fresenius failed to argue its tortious interference claim in its opening brief....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.